Please assess the completion status of the following clinical trial:

Trial Title: Heme Oxygenase (HO) Activity and Adenosine Induced Vasodilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* at least 18 and no older than 65 on the day of first dosing~* healthy~* Quetelet Index (Body Mass Index) of 18 to 30 kg/m2~* In general, results of haematology and chemistry should be within the laboratory's reference ranges. Determinants of renal and hepatic function should be within twice the upper limit of normal range.~Exclusion Criteria:~* Documented history of sensitivity / idiosyncrasy to medicinal products or excipients~* history of smoking within the past year~* history of or current abuse of drugs, alcohol and/or solvents~* Current use of any (over the counter) medication potentially influencing heme oxygenase or the cardiovascular system~* Inability to understand the nature and extent of the trial and the procedures required~* Participation to a drug trial within 60 days prior to the first dose~* Febrile illness within 3 days before the first dose~* Heterozygosity (LS) or homozygosity (LL) with regard to the number of GT repeats in the HO-1 promoter region

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): L-arginine treatment first, heme arginate treatment second
- 2 (Type: EXPERIMENTAL): Heme arginate treatment first, L-arginine treatment second

Based on this trial design, predict the completion outcome and termination type (if applicable).